Podcasts
Deep dives into market trends, company analysis, and expert interviews
Lake Resources (ASX: LKE): Argentina’s lithium opportunity
James Whelan speaks with David Dickson, Managing Director and CEO of Lake Resources (ASX: LKE), and His Excellency Máximo Gowland, Argentina’s Ambassador to Australia, at IMARC in Sydney. They discuss how Australian mining expertise could support Argentina’s lithium and copper sectors, the RIGI investment framework and the development of Lake’s Kachi lithium brine project in Catamarca. Dickson explains Kachi’s environmental approval and the next steps, including offtake agreements, financing and further development work. Lake’s RIGI application remains pending. The conversation also covers direct lithium extraction (DLE), supply chains and management’s development ambitions. Recorded 29 October 2026. Development plans, production timing and market views discussed in this interview are forward-looking and conditional. Environmental outcomes depend on the specific project and process. For more interviews, visit smallcaps.com.au. This content is for information only and is not financial advice. Topics discussed • Australia–Argentina mining cooperation • RIGI and Lake’s pending application • Kachi’s environmental approval and next steps • Direct lithium extraction and supply chains • Management’s development ambitions Chapters 0
BCAL Diagnostics (ASX: BDX): Jayne Shaw on early cancer detection
James Whelan speaks with Jayne Shaw, Non-Executive Chair of BCAL Diagnostics (ASX: BDX), about the company’s move from research and development to commercialising blood-based cancer tests. Shaw discusses BREASTESTplus alongside mammography, GP referral infrastructure, clinician education and BCAL’s licensed Avantect tests. She also explains the team’s focus on test sales and commercial execution under CEO Anne-Louise (Annie) Arnett. Management’s plans discussed in this interview include a November 2026 BREASTESTplus update, US validation work with Sonic Healthcare and an MSAC reimbursement application for pancreatic testing. Planned development, validation and reimbursement steps remain conditional. Recorded 26 October 2026. Diagnostic tests require clinical interpretation and follow-up and do not replace established screening or medical advice. For more interviews, visit smallcaps.com.au. This content is for information only and is not financial or medical advice. Chapters 0
Theory of Thing: Southern Bluefin tuna catch limit rises
Australian statutory fishing rights give their owners access to a capped quantity of fish from a particular species and area. Anthony Ciconte of Atlantis Fisheries Consulting Group explains how the rights work and how catch limits are set, with the higher global catch limit for Southern Bluefin tuna as the starting point. Key Highlights A statutory fishing right allows its owner to take a set quantity of a species from a particular area each year, subject to catch limits. The rights are described as lasting in perpetuity, while the amount that can be caught is managed and capped. Fishing rights can be left unharvested, with no obligation to catch fish each year. Scientific methods are used to assess fish stocks and inform annual catch limits. The global catch limit for Southern Bluefin tuna had increased the previous week. About Theory of Thing Theory of Thing is an investment podcast powered by SmallCaps. Disclaimer This podcast is for educational and entertainment purposes only and should not be considered financial advice. All investments carry risk, including the potential loss of principal. Listeners should conduct their own research and consider seeking professional financial advice before making investment decisions. #SmallCaps #ASXInvesting # #AustralianStocks #Investing #Podcast
Ceryvyn sets safety gates for inhaled CYV-101 in LAM
James Whelan speaks with Dr Jeremy Levin, Executive Chair of Ceryvyn Therapeutics (ASX: CYV), about investigational CYV-101 and the company’s LAM development program. Topics include the proposed VEGF-C/D mechanism, nebulised delivery, further inhaled safety work, scientific and patient input, and disciplined investment against development stage gates. Levin describes a potential Australian study of fewer than 20 patients, conditional on successful safety work and progression through stage gate one. Xenon MRI is one measurement approach under consideration. CYV-101 remains investigational. Prior ophthalmology exposure does not establish the safety or effectiveness of an inhaled treatment for LAM. Ceryvyn was formerly known as Opthea. More interviews: smallcaps.com.au. Information only; not financial advice. #SmallCaps #ASX #CYV #Ceryvyn #LAM
The nuclear comeback: uranium market overview with James Whelan
James Whelan opens Small Caps’ “Glow Up” uranium webinar with an overview of nuclear power demand, reactor construction, data-centre electricity requirements and the long lead times involved in bringing new uranium supply to market. He introduces Alex Cheeseman of Greenvale Energy, Murray Hill of Elevate Uranium and Peter Moorhouse of Basin Energy, before outlining the demand scenarios and supply considerations that frame their presentations. This segment contains the webinar introduction and market overview; the company presentations are separate recordings. Recorded on 16 October 2026. Company statements and proposed work programmes reflect the presentation at that time. General information only, not financial advice. Do your own research and seek independent professional advice.
Basin Energy (ASX: BSN): uranium optionality across Sweden, Queensland and Canada
Basin Energy managing director Peter Moorhouse outlines the company’s uranium exposure in Sweden, Queensland and Canada, alongside its near-term focus on the Newmans rare earth discovery. The presentation covers Nordic exploration targets, the Sybella-Barkly portfolio near Mount Isa and the geological rationale for further uranium exploration. Moorhouse also discusses the Marshall sale, retained exposure through Green Canada and the Geikie project in the Athabasca Basin. In the Q&A, he explains the reasoning behind retaining transaction optionality and balancing near-term rare earth work with longer-term uranium opportunities. Exploration interpretations and proposed programmes remain subject to further work and results. Recorded on 16 October 2026. Company statements and proposed work programmes reflect the presentation at that time. General information only, not financial advice. Do your own research and seek independent professional advice.
Elevate Uranium (ASX: EL8): U-pgrade pilot plant, Marenica and Koppies
Elevate Uranium managing director and CEO Murray Hill discusses the company’s U-pgrade processing technology and uranium projects in Namibia and Australia. Hill outlines the reported results from the first four pilot-plant stages and explains the remaining uranium flotation stage. He discusses the potential processing and environmental benefits, while noting that further pilot work and studies are needed to establish performance and costs. The presentation also covers Marenica and Koppies, resource drilling, Australian projects and planned studies. The Q&A addresses potential licensing and partnerships, with Elevate’s own projects remaining the immediate focus. Recorded on 16 October 2026. Company statements and proposed work programmes reflect the presentation at that time. General information only, not financial advice. Do your own research and seek independent professional advice.
Greenvale Energy (ASX: GRV): Thunderball, Pine Creek and the uranium exploration plan
Greenvale Energy managing director Alex Cheeseman outlines the company’s Northern Territory uranium exploration strategy, including the Thunderball project, Douglas River and the proposed acquisition of Pine Creek uranium rights from Patronus Resources. The presentation covers the Hayes Creek fault zone, field work and target generation, permitting and proposed drilling following the wet season. In the Q&A, Cheeseman discusses Queensland uranium policy, the decision to prioritise Northern Territory exploration, capital allocation and the strategic value of a potential new discovery. Exploration success, transaction completion and development outcomes remain uncertain. Recorded on 16 October 2026. Company statements and proposed work programmes reflect the presentation at that time. General information only, not financial advice. Do your own research and seek independent professional advice.
Camplify's next chapter: Justin Hales on margins and MyWay
James Whelan speaks with Camplify founder and CEO Justin Hales about operational efficiency, margins, Club Camplify and MyWay Mutual. They also discuss booking behaviour, the RV sales and rental ecosystem, and the seasonal cash-flow indicators Justin watches. Camplify Holdings (ASX: CHL) reported FY26 adjusted EBITDA of A$0.3 million, compared with a loss of A$10.4 million a year earlier. Its FY26 statutory result was a net loss of A$0.8 million. Future plans and outlook in this interview are management's views, not guarantees. Podcast chapters: 0
Firmus float fallout, AI chip costs & markets | Theory of Thing
Theory of Thing, powered by Small Caps. Recorded 9 October 2026. James Whelan and Heath Moss discuss: • The pulled Firmus float and AI infrastructure valuations • GPU useful life, depreciation and capital expenditure • Equity markets, bond yields and ETFs • Gold, oil and copper • This week’s small-cap headlines General information only. This podcast does not provide personal financial advice. Chapters:
Small Caps market wrap: higher yields and a 25bp RBA rise
Higher bond yields, a 25 basis point RBA rate rise and a relatively steady equity market set the scene for this episode of the Small Caps Spotlight podcast. James Whelan and Heath Moss also discuss Small Caps’ move into new offices and upcoming industry events. Key Highlights The RBA raised rates by 25 basis points. Government spending was described as 28% of GDP, a record according to the discussion. The S&P 500 was trading between 7,660 and 7,760. The US ten-year yield reached a level last seen in 2002, according to the discussion. Small Caps moved into new offices. The Gold Events conference, MicroCaps Conference and IMARC were highlighted as upcoming events. About Small Caps Small Caps covers Australian small-cap companies and market developments. The podcast is powered by Small Caps. Disclaimer This podcast is for educational and entertainment purposes only and should not be considered financial advice. All investments carry risk, including the potential loss of principal. Listeners should conduct their own research and consider seeking professional financial advice before making investment decisions. #SmallCaps #ASXInvesting # #AustralianStocks #Investing #Podcast
Iltani Resources: Orient West drilling extends beyond 2025 resource
Orient West drilling has returned strong results beyond the area covered by Iltani Resources’ 2025 mineral resource. Managing Director Donald Garner discusses how the results may feed into the next resource calculation, alongside planned drilling, ore-sorting test work and the scoping study. Key Highlights Orient West results followed up OR137, which hit a VTEM target at the end of 2025, and are to be included in the next Orient resource calculation. About 45 to 50 holes from the 110-hole programme remained at the AST lab in Townsville awaiting results. TOMRA ore-sorting test work was scheduled for 7 and 8 October, followed by flotation test work at Core Metallurgy in Brisbane. Garner described a hypothetical case where ore sorting could reduce annual plant throughput from 5 million tonnes to 0.5 to 1 million tonnes. The potential cost and plant benefits remain subject to test work. Iltani is targeting an early 2027 scoping study and plans diamond drilling at Isabel. Boonmoo returned no material hit. Union Jack drilling intersected sulfides, mainly pyrrhotite and arsenopyrite, which were not the target sulfides; down-hole work is planned to help guide follow-up drilling. About Iltani Resources Iltani Resources (ASX: ILT) is advancing the Orient project in the Herberton region of North Queensland. The company is assessing Orient as a standalone project, with satellite deposits in the district as potential additions. Disclaimer This podcast is for educational and entertainment purposes only and should not be considered financial advice. All investments carry risk, including the potential loss of principal. Listeners should conduct their own research and consider seeking professional financial advice before making investment decisions. #SmallCaps #ASXInvesting #ILT.ASX #AustralianStocks #Investing #Podcast